We utilized Principal component analysis (PCA) scores to quantify the overall rank of this co-expressed gene panel.6 Across all the drugs and tumor types examined, the median ln(IC50) in cell lines with high expressions of genes in the panel was lower in the majority of cases (57 out of 73; Supplementary Figs. S10–13), consistent with our hypothesis that high expression of factors in the gene panel is correlated with hypersensitivity to PARP inhibitors/cisplatin. The gene discussed is PARP1; the disease is neoplasm.